Primary sclerosing cholangitis: Resect, dilate, or transplant?

Steven A. Ahrendt, Henry A. Pitt, Anthony N. Kalloo, Anthony C. Venbrux, Andrew S. Klein, H. Franklin Herlong, Joann Coleman, Keith D. Lillemoe, John L. Cameron

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Objective: The current study examines the results of extrahepatic biliary resection, nonoperative endoscopic biliary dilation with or without percutaneous stenting, and liver transplantation in the management of patients with primary sclerosing cholangitis (PSC). Summary Background Data: Primary sclerosing cholangitis is a progressive inflammatory disease leading to secondary biliary cirrhosis. The most effective management of sclerosing cholangitis before the onset of cirrhosis remains unclear. Methods: From 1980 to 1994, 146 patients with PSC were managed with either resection of the extrahepatic bile ducts and long-term transhepatic stenting (50 patients), nonoperative endoscopic biliary dilation with or without percutaneous stenting (54 patients), medical therapy (28 patients), and/or liver transplantation (21 patients). Results: Procedure-related morbidity and mortality rates were similar between surgically resected and nonoperatively managed patients. In noncirrhotic patients, the serum bilirubin level was significantly (p < 0.05) reduced from preoperative levels (8.3 ± 1.5 mg/dL) 1 (1.7 ± 0.4 mg/dL) and 3 (2.7 ± 0.9 mg/dL) years after resection, but not after endoscopic or percutaneous management. For noncirrhotic PSC patients, overall 5-year survival (85% vs. 59%) and survival until death or transplantation (82% vs. 46%) were significantly longer (p < 0.05) after resection than after nonoperative dilation with or without stenting. For cirrhotic patients, survival after liver transplantation was longer than after resection or nonoperative dilation with or without stenting. Five patients developed cholangiocarcinoma, including three (6%) of the nonoperatively managed patients but none of the resected patients. Conclusions: In carefully selected noncirrhotic patients with PSC, resection and long-term stenting remains a good option. Patients with cirrhosis should undergo liver transplantation.

Original languageEnglish (US)
Pages (from-to)412-423
Number of pages12
JournalAnnals of surgery
Volume227
Issue number3
DOIs
StatePublished - Mar 1 1998
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Transplants
Liver Transplantation
Dilatation
Survival
Fibrosis
Extrahepatic Bile Ducts
Cholangiocarcinoma
Biliary Liver Cirrhosis
Bilirubin

ASJC Scopus subject areas

  • Surgery

Cite this

Ahrendt, S. A., Pitt, H. A., Kalloo, A. N., Venbrux, A. C., Klein, A. S., Herlong, H. F., ... Cameron, J. L. (1998). Primary sclerosing cholangitis: Resect, dilate, or transplant? Annals of surgery, 227(3), 412-423. https://doi.org/10.1097/00000658-199803000-00014

Primary sclerosing cholangitis : Resect, dilate, or transplant? / Ahrendt, Steven A.; Pitt, Henry A.; Kalloo, Anthony N.; Venbrux, Anthony C.; Klein, Andrew S.; Herlong, H. Franklin; Coleman, Joann; Lillemoe, Keith D.; Cameron, John L.

In: Annals of surgery, Vol. 227, No. 3, 01.03.1998, p. 412-423.

Research output: Contribution to journalArticle

Ahrendt, SA, Pitt, HA, Kalloo, AN, Venbrux, AC, Klein, AS, Herlong, HF, Coleman, J, Lillemoe, KD & Cameron, JL 1998, 'Primary sclerosing cholangitis: Resect, dilate, or transplant?', Annals of surgery, vol. 227, no. 3, pp. 412-423. https://doi.org/10.1097/00000658-199803000-00014
Ahrendt, Steven A. ; Pitt, Henry A. ; Kalloo, Anthony N. ; Venbrux, Anthony C. ; Klein, Andrew S. ; Herlong, H. Franklin ; Coleman, Joann ; Lillemoe, Keith D. ; Cameron, John L. / Primary sclerosing cholangitis : Resect, dilate, or transplant?. In: Annals of surgery. 1998 ; Vol. 227, No. 3. pp. 412-423.
@article{eb008a3c47294faca7ecd9b2a486d807,
title = "Primary sclerosing cholangitis: Resect, dilate, or transplant?",
abstract = "Objective: The current study examines the results of extrahepatic biliary resection, nonoperative endoscopic biliary dilation with or without percutaneous stenting, and liver transplantation in the management of patients with primary sclerosing cholangitis (PSC). Summary Background Data: Primary sclerosing cholangitis is a progressive inflammatory disease leading to secondary biliary cirrhosis. The most effective management of sclerosing cholangitis before the onset of cirrhosis remains unclear. Methods: From 1980 to 1994, 146 patients with PSC were managed with either resection of the extrahepatic bile ducts and long-term transhepatic stenting (50 patients), nonoperative endoscopic biliary dilation with or without percutaneous stenting (54 patients), medical therapy (28 patients), and/or liver transplantation (21 patients). Results: Procedure-related morbidity and mortality rates were similar between surgically resected and nonoperatively managed patients. In noncirrhotic patients, the serum bilirubin level was significantly (p < 0.05) reduced from preoperative levels (8.3 ± 1.5 mg/dL) 1 (1.7 ± 0.4 mg/dL) and 3 (2.7 ± 0.9 mg/dL) years after resection, but not after endoscopic or percutaneous management. For noncirrhotic PSC patients, overall 5-year survival (85{\%} vs. 59{\%}) and survival until death or transplantation (82{\%} vs. 46{\%}) were significantly longer (p < 0.05) after resection than after nonoperative dilation with or without stenting. For cirrhotic patients, survival after liver transplantation was longer than after resection or nonoperative dilation with or without stenting. Five patients developed cholangiocarcinoma, including three (6{\%}) of the nonoperatively managed patients but none of the resected patients. Conclusions: In carefully selected noncirrhotic patients with PSC, resection and long-term stenting remains a good option. Patients with cirrhosis should undergo liver transplantation.",
author = "Ahrendt, {Steven A.} and Pitt, {Henry A.} and Kalloo, {Anthony N.} and Venbrux, {Anthony C.} and Klein, {Andrew S.} and Herlong, {H. Franklin} and Joann Coleman and Lillemoe, {Keith D.} and Cameron, {John L.}",
year = "1998",
month = "3",
day = "1",
doi = "10.1097/00000658-199803000-00014",
language = "English (US)",
volume = "227",
pages = "412--423",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Primary sclerosing cholangitis

T2 - Resect, dilate, or transplant?

AU - Ahrendt, Steven A.

AU - Pitt, Henry A.

AU - Kalloo, Anthony N.

AU - Venbrux, Anthony C.

AU - Klein, Andrew S.

AU - Herlong, H. Franklin

AU - Coleman, Joann

AU - Lillemoe, Keith D.

AU - Cameron, John L.

PY - 1998/3/1

Y1 - 1998/3/1

N2 - Objective: The current study examines the results of extrahepatic biliary resection, nonoperative endoscopic biliary dilation with or without percutaneous stenting, and liver transplantation in the management of patients with primary sclerosing cholangitis (PSC). Summary Background Data: Primary sclerosing cholangitis is a progressive inflammatory disease leading to secondary biliary cirrhosis. The most effective management of sclerosing cholangitis before the onset of cirrhosis remains unclear. Methods: From 1980 to 1994, 146 patients with PSC were managed with either resection of the extrahepatic bile ducts and long-term transhepatic stenting (50 patients), nonoperative endoscopic biliary dilation with or without percutaneous stenting (54 patients), medical therapy (28 patients), and/or liver transplantation (21 patients). Results: Procedure-related morbidity and mortality rates were similar between surgically resected and nonoperatively managed patients. In noncirrhotic patients, the serum bilirubin level was significantly (p < 0.05) reduced from preoperative levels (8.3 ± 1.5 mg/dL) 1 (1.7 ± 0.4 mg/dL) and 3 (2.7 ± 0.9 mg/dL) years after resection, but not after endoscopic or percutaneous management. For noncirrhotic PSC patients, overall 5-year survival (85% vs. 59%) and survival until death or transplantation (82% vs. 46%) were significantly longer (p < 0.05) after resection than after nonoperative dilation with or without stenting. For cirrhotic patients, survival after liver transplantation was longer than after resection or nonoperative dilation with or without stenting. Five patients developed cholangiocarcinoma, including three (6%) of the nonoperatively managed patients but none of the resected patients. Conclusions: In carefully selected noncirrhotic patients with PSC, resection and long-term stenting remains a good option. Patients with cirrhosis should undergo liver transplantation.

AB - Objective: The current study examines the results of extrahepatic biliary resection, nonoperative endoscopic biliary dilation with or without percutaneous stenting, and liver transplantation in the management of patients with primary sclerosing cholangitis (PSC). Summary Background Data: Primary sclerosing cholangitis is a progressive inflammatory disease leading to secondary biliary cirrhosis. The most effective management of sclerosing cholangitis before the onset of cirrhosis remains unclear. Methods: From 1980 to 1994, 146 patients with PSC were managed with either resection of the extrahepatic bile ducts and long-term transhepatic stenting (50 patients), nonoperative endoscopic biliary dilation with or without percutaneous stenting (54 patients), medical therapy (28 patients), and/or liver transplantation (21 patients). Results: Procedure-related morbidity and mortality rates were similar between surgically resected and nonoperatively managed patients. In noncirrhotic patients, the serum bilirubin level was significantly (p < 0.05) reduced from preoperative levels (8.3 ± 1.5 mg/dL) 1 (1.7 ± 0.4 mg/dL) and 3 (2.7 ± 0.9 mg/dL) years after resection, but not after endoscopic or percutaneous management. For noncirrhotic PSC patients, overall 5-year survival (85% vs. 59%) and survival until death or transplantation (82% vs. 46%) were significantly longer (p < 0.05) after resection than after nonoperative dilation with or without stenting. For cirrhotic patients, survival after liver transplantation was longer than after resection or nonoperative dilation with or without stenting. Five patients developed cholangiocarcinoma, including three (6%) of the nonoperatively managed patients but none of the resected patients. Conclusions: In carefully selected noncirrhotic patients with PSC, resection and long-term stenting remains a good option. Patients with cirrhosis should undergo liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0031887849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031887849&partnerID=8YFLogxK

U2 - 10.1097/00000658-199803000-00014

DO - 10.1097/00000658-199803000-00014

M3 - Article

C2 - 9527065

AN - SCOPUS:0031887849

VL - 227

SP - 412

EP - 423

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -